Fund shareholders of 10X Genomics Inc
ISIN US88025U1097 · United States · LEI 5493003Z6741WNLG7H43
- Fund shareholders
- 301
- Of which ETFs
- 70 231 other funds
- Value held
- ≈ 2.2B $ 2.2B $ · 22.2K € · 9.5M SEK
- Share of capital
- 44.0 % of 127.7M shares on Dec 31, 2025
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| GVC GAESCO CROSSOVER, FI GVC GAESCO CROSSOVER-VOA MIXTO INTERNACIONAL GVC GAESCO GESTIÓN, SGIIC, S.A. | 22.2K € | 0.26 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 9.39 % | as of Jul 31, 2026 ↗ |
| ARK Innovation ETF ARK ETF Trust | 3.30 % | as of Jul 31, 2026 ↗ |
| Global X Genomics & Biotechnology ETF GLOBAL X FUNDS | 3.23 % | as of May 31, 2026 ↗ |
| American Beacon ARK Transformational Innovation Fund AMERICAN BEACON FUNDS | 3.13 % | as of Jun 30, 2026 ↗ |
| Simplify Health Care ETF Simplify Exchange Traded Funds | 3.13 % | as of Jun 30, 2026 ↗ |
| Fidelity Disruptive Medicine ETF Fidelity Covington Trust | 3.11 % | as of May 31, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 2.27 % | as of Jul 31, 2026 ↗ |
| ALGER HEALTH SCIENCES FUND ALGER FUNDS | 2.26 % | as of Jul 31, 2026 ↗ |
| Lord Abbett Health Care Fund LORD ABBETT SECURITIES TRUST | 2.16 % | as of Jul 31, 2026 ↗ |
| Nuveen Small Cap Value Opportunities Fund Nuveen Investment Trust | 2.14 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 299 | +18 | 56,192,266 | +3.2 % |
| 2026Q2 | 281 | +16 | 54,466,548 | +3.1 % |
| 2026Q1 | 265 | +21 | 52,826,790 | +3.2 % |
| 2025Q4 | 244 | +27 | 51,175,690 | +14.0 % |
| 2025Q3 | 217 | +8 | 44,905,534 | +6.8 % |
| 2025Q2 | 209 | -3 | 42,047,418 | -5.0 % |
| 2025Q1 | 212 | -21 | 44,250,365 | -7.3 % |
| 2024Q4 | 233 | -21 | 47,741,162 | -2.9 % |
| 2024Q3 | 254 | -18 | 49,190,072 | +6.9 % |
| 2024Q2 | 272 | -23 | 45,999,528 | -1.2 % |
| 2024Q1 | 295 | +7 | 46,566,261 | +8.4 % |
| 2023Q4 | 288 | 42,942,096 |
Institutional managers
322 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 17,740,972 | 376.6M $ | as of Mar 31, 2026 |
| ARK Investment Management LLC | 11,717,317 | 248.8M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 10,079,913 | 214M $ | as of Mar 31, 2026 |
| Quantinno Capital Management LP | 5,411,761 | 114.9M $ | as of Mar 31, 2026 |
| Sumitomo Mitsui Trust Group, Inc. | 5,110,214 | 108.5M $ | as of Mar 31, 2026 |
| Amova Asset Management Americas, Inc. | 5,104,178 | 108.3M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 3,971,800 | 84.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,904,228 | 61.7M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,656,353 | 56.4M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 2,588,795 | 55M $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 2,538,256 | 53.7M $ | as of Mar 31, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2,283,424 | 48.5M $ | as of Mar 31, 2026 |
| Casdin Capital, LLC | 2,275,000 | 48.3M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 2,068,414 | 43.9M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 2,042,950 | 43.4M $ | as of Mar 31, 2026 |
| Capital World Investors | 1,452,300 | 30.8M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 1,279,382 | 27.2K $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,127,056 | 23.9M $ | as of Mar 31, 2026 |
| Blue Water Life Science Advisors, LP | 1,090,000 | 23.1M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 1,048,005 | 22.2M $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 1,008,739 | 21.4M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 989,522 | 21M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 964,579 | 20.5M $ | as of Mar 31, 2026 |
| Connor, Clark & Lunn Investment Management Ltd. | 938,408 | 19.9M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 785,505 | 15.6M $ | as of Mar 31, 2026 |
Declared shareholders of 10X Genomics Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| T. Rowe Price Associates, Inc. | 11.70 % | 14,044,020 | as of Aug 31, 2026 · SCHEDULE 13G |
| ARK Investment Management LLC and 1 other | 8.56 % | 10,003,058 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of 10X Genomics Inc". https://titelia.com/en/stocks/10x-genomics-inc-US88025U1097